Arcutis Biotherapeutics, Inc. filed a Form 8-K on October 28, 2026, disclosing that its Board of Directors appointed Dr. Robert Scott as a new independent director effective October 23, 2026, and expanded the board from ten to eleven members.

Key Highlights

  • Board expansion: The authorized number of directors was increased from ten to eleven on October 23, 2026.
  • New director: Dr. Robert Scott, age 73, was appointed as a Class II director with a term expiring at the 2028 annual meeting of stockholders.
  • Committee assignment: Dr. Scott was also appointed to the Nominating and Corporate Governance Committee.
  • Initial equity grant: Dr. Scott received an initial stock option award exercisable for 20,507 shares of the company's common stock upon the effective date of his appointment.
  • Annual compensation: Dr. Scott is eligible for a prorated annual equity award fair valued at approximately $350,000 (allocated 65% to stock options and 35% to restricted stock units), plus a prorated annual cash retainer of $50,000 for board service and $5,000 for committee service.
  • Independence determination: The board determined that Dr. Scott qualifies as an independent director under applicable SEC rules and Nasdaq listing standards.

Arcutis Biotherapeutics Appoints Veteran Pharmaceutical Executive Dr. Robert Scott

According to the filing, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) reported that its board appointed Dr. Robert Scott on October 23, 2026, following a vote to expand the board's authorized size from ten to eleven directors. Dr. Scott was designated a Class II director, with his term set to expire at the company's 2028 annual meeting of stockholders, or upon his earlier death, resignation, disqualification, or removal, according to the filing.

The filing describes Dr. Scott's background as spanning several decades of pharmaceutical industry leadership. He most recently served as Chief Medical Officer and Head of Development of AbbVie Inc. from April 2016 until his retirement in April 2020. Prior to that role, he served as Vice President, Global Development and Therapeutic Area Head at Amgen Inc. from November 2010 to March 2016, and held earlier positions at Cerenis Therapeutics, AtheroGenics, Inc., Pfizer Inc., and Janssen. The filing also notes that Dr. Scott served as a non-voting industry representative on the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee from January 2012 to December 2016.

As compensation, the filing states that Dr. Scott's initial stock option award will vest in three equal annual installments on the anniversary of his appointment date. The prorated annual equity award will vest immediately before the annual meeting following the grant date, in each case subject to his continued service. The company also disclosed it will enter into an indemnification agreement with Dr. Scott on the form previously approved by the board and used with other directors. The filing further states there is no arrangement or understanding between Dr. Scott and any other person pursuant to which he was selected, and that there are no family relationships between Dr. Scott and any of the company's directors or executive officers.

What Was Disclosed

Arcutis Biotherapeutics filed an 8-K disclosing the October 23, 2026 appointment of Dr. Robert Scott as an independent Class II director and member of the Nominating and Corporate Governance Committee, along with the associated compensation terms under the company's non-employee director program.